drugset / Trial / NCT07079267

Olpasiran Expanded Access Program

NCT07079267 ↗

Expanded access Available Amgen

Summary

Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Olpasiran Unknown — —

Indications

No indication recorded.